Your Health, We Care
Release date: 2026-05-12 16:36:25 Recommended: 7
The standard dosing regimen for palbociclib is 125 mg taken orally once daily for 3 consecutive weeks followed by 1 week off. Tablets can be taken with or without food, while capsules must be taken with food. Patients should be encouraged to take the medication at approximately the same time each day. If vomiting or a missed dose occurs, do not make up the dose that day; simply take the next dose as scheduled. Regular monitoring of complete blood count is required during treatment: before treatment initiation, on Day 1 and Day 15 of the first two cycles, and on Day 1 of subsequent cycles. If only Grade 1 or 2 neutropenia occurs in the first 6 cycles, monitoring may be done every 3 months thereafter. Additionally, actively monitor for pulmonary symptoms of ILD/pneumonitis. For dose adjustments, interruption, reduction, or delay of treatment is recommended in case of Grade 3 or 4 neutropenia; dose reduction should be considered for delayed recovery from hematologic toxicity or recurrent Grade 3 neutropenia. Non-hematologic toxicities should be managed according to severity grading.
Facing a diagnosis of metastatic breast cancer, patients need to give themselves time to adjust to a new normal. Methods to manage stress include relaxation techniques, artistic creation, exercise, spending time with pets, etc., which can help reduce tension and improve sleep. When communicating with children, consider the child's age and level of understanding; seek help from a social worker or psychiatrist if needed. In terms of interpersonal relationships, when dating, try introductions through friends or health condition-specific dating websites, and build self-confidence with a new look. Concerns about intimate relationships are normal; regular communication with a partner, open and honest discussions, and even considering couples counseling can help both parties cope together. Additionally, good nutrition is essential – eating well helps the body maintain strength and repair tissue damage. Always consult a doctor before making changes to diet or exercise.
On February 3, 2015, palbociclib received its first FDA approval in the United States as the first-in-class CDK4/6 inhibitor, in combination with letrozole for endocrine-based therapy in postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer. Over the past decade, this drug has profoundly transformed the treatment landscape for HR+/HER2- metastatic breast cancer. To date, more than 22,000 prescribing physicians have chosen palbociclib, and over 200,000 patients have received a prescription for palbociclib.
